US · Healthcare · Medical Devices
EPS came in at -0.14 against a street estimate of -0.23 — a beat of 39.1%.
Analysts rate 10X Genomics Inc a buy (6 buy, 12 hold, 0 sell out of 18) with an average price target of $77.50.
CONFIDENT 10x reported $151 million of Q2 revenue, strong consumables growth and exceptional Atera demand. Guidance rose, but shipments remain manufacturing-constrained and Q3 revenue should dip modestly before an Atera-driven Q4 increase. Q2 FY26 APAC comparisons were affected by approximately $4 million of China purchasing pulled forward into the prior-year period. Analysts focused on Atera’s manufacturing ramp, utilization, market opportunity and launch risks, plus Chromium growth and AI demand. Management emphasized exceptional demand, constrained near-term production and strong longer-term adoption potential. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 13.53% |
| BlackRock Inc | 8.29% |
| ARK Investment Management LLC | 7.68% |
| Vanguard Portfolio Management, LLC | 5.36% |
| Quantinno Capital Management LP | 4.20% |
| Vanguard Capital Management, LLC | 3.90% |
| T. Rowe Price Associates, Inc. | 3.48% |
| Sumitomo Mitsui Trust Group Inc | 3.22% |
| Document | Date |
|---|---|
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $150.7 million, up 1% from $149.0 million in the third quarter of 2025. • Gross margin increased t | 2026-11-05 |
| Board / officer change · Q4 2026 OTHER NOTABLE POINTS • 10x Genomics appointed Ansuman Satpathy and Joseph Gilliam as Class III directors effective October 28, 2026. Their terms run | 2026-11-02 |
| Quarterly report · Q2 2026 10x GENOMICS, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue (Q2 2026): $151.0 million (down 12.7% vs Q2 2025's $172.9 million) - Products | 2026-08-07 |
| Results announced · Q3 2026 10X GENOMICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $151.0 million (down 13% vs. Q2 2025's $172.9 million); excluding | 2026-08-06 |
| Shareholder vote results · Q2 2026 10X GENOMICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held June 4, 2026 • Quorum achieved: 198,815,518 votes cast repr | 2026-06-08 |
| Quarterly report · Q1 2026 10X GENOMICS, INC. – Q1 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue (Q1 2026): $150.8 million, down slightly from $154.9 million in | 2026-05-08 |
| Results announced · Q2 2026 10X GENOMICS Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q1 2026 Revenue: $150.8 million – down 3% year-over-year, but up 9% excluding $16. | 2026-05-07 |
| Proxy statement · Q2 2026 10X GENOMICS, INC. — PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal One: Election of Class I directors (three-year terms expirin | 2026-04-24 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for 10X Genomics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.